Australia markets close in 2 hours 40 minutes

Alector, Inc. (0Z2.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
20.00+0.20 (+1.01%)
At close: 8:13AM CEST
Full screen
Previous close19.80
Open20.00
Bid0.00 x 0
Ask0.00 x 0
Day's range20.00 - 20.00
52-week range20.00 - 20.00
Volume35
Avg. volumeN/A
Market cap1.408B
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)-2.31
Earnings date08 Nov 2021 - 12 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est44.00
  • Simply Wall St.

    Those who invested in Alector (NASDAQ:ALEC) a year ago are up 134%

    Alector, Inc. ( NASDAQ:ALEC ) shareholders might understandably be very concerned that the share price has dropped 33...

  • GlobeNewswire

    Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company’s Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology. “Betsy is a highly-regarded leader with unmatched clinical

  • GlobeNewswire

    Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)

    Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 in people with amyotrophic lateral sclerosis (ALS) who carry a C9orf72 mut